Valve-in-Valve Implantation of a Sapien 3 Transcatheter Heart Valve for Reduction of Paravalvular Regurgitation Despite Optimal Placement of the First Transcatheter Heart Valve

2017 ◽  
Vol 33 (4) ◽  
pp. 555.e13-555.e15
Author(s):  
Ayoub El Hammiri ◽  
Jeannot Potvin ◽  
Jean-François Gobeil ◽  
Nicolas Noiseux ◽  
Louis-Mathieu Stevens ◽  
...  
Keyword(s):  
Heart Valve ◽  
Optimal Placement ◽  
Transcatheter Heart Valve ◽  
Valve In Valve ◽  
Sapien 3 ◽  
Valve Implantation

scholarly journals One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart Valve

2020 ◽  
Vol 5 (11) ◽  
pp. 1245 ◽  
Author(s):  
Brian Whisenant ◽  
Samir R. Kapadia ◽  
Mackram F. Eleid ◽  
Susheel K. Kodali ◽  
James M. McCabe ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Heart Valve ◽  
Transcatheter Heart Valve ◽  
Valve In Valve ◽  
Sapien 3 ◽  
One Year

Early outcomes of percutaneous pulmonary valve implantation using the Edwards SAPIEN 3 transcatheter heart valve system

2019 ◽  
Vol 14 (13) ◽  
pp. 1378-1385 ◽  
Author(s):  
Sebastien Hascoet ◽  
Robert Dalla Pozza ◽  
Jamie Bentham ◽  
Ronald Giacomo Carere ◽  
Majed Kanaan ◽  
...  
Keyword(s):  
Heart Valve ◽  
Pulmonary Valve ◽  
Valve System ◽  
Percutaneous Pulmonary Valve Implantation ◽  
Transcatheter Heart Valve ◽  
Edwards Sapien ◽  
Sapien 3 ◽  
Valve Implantation ◽  
Percutaneous Pulmonary Valve ◽  
Pulmonary Valve Implantation

scholarly journals Optimising the Haemodynamics of Aortic Valve-in-valve Procedures

2017 ◽  
Vol 12 (01) ◽  
pp. 40 ◽  
Author(s):  
Ren Jie Yao ◽  
Matheus Simonato ◽  
Danny Dvir ◽  
◽  
◽  
...  
Keyword(s):  
Aortic Valve ◽  
Heart Valve ◽  
Standard Of Care ◽  
Common Adverse Event ◽  
Mechanical Valves ◽  
Transcatheter Heart Valve ◽  
Implantation Depth ◽  
Valve In Valve ◽  
Transcatheter Valve ◽  
Valve Implantation

Bioprosthetic surgical valves are increasingly implanted during cardiac surgery, instead of mechanical valves. These tissue valves are associated with limited durability and as a result transcatheter valve-in-valve procedures are performed to treat failed bioprostheses. A relatively common adverse event of aortic valve-in-valve procedures is residual stenosis. Larger surgical valve size, supra-annular transcatheter heart valve type, as well as higher transcatheter heart valve implantation depth, have all been shown to reduce the incidence of elevated post-procedural gradients. With greater understanding of technical considerations and surgical planning, valve-invalve procedures could be more effective and eventually may become the standard of care for our increasingly ageing and comorbid population with failed surgical bioprostheses.

scholarly journals Early Safety and Efficacy of Sapien 3 20 mm Transcatheter Heart Valve Implantation in Small Japanese Body Size

2018 ◽  
Vol 21 (5) ◽  
pp. E341-E344
Author(s):  
Kentaro Meguro ◽  
Ryota Kakizaki ◽  
Takuya Hashimoto ◽  
Tomoyoshi Yanagisawa ◽  
Toshimi Koitabashi ◽  
...  
Keyword(s):  
Body Size ◽  
Aortic Valve ◽  
Heart Valve ◽  
Small Body ◽  
Japanese Patients ◽  
Aortic Valve Area ◽  
Small Body Size ◽  
Transcatheter Heart Valve ◽  
Sapien 3 ◽  
Valve Implantation

Background: Transcatheter aortic valve implantation (TAVI) is effective in treating severe aortic stenosis in inoperable or high-risk surgical patients, however, the little is known about outcomes after Sapien 3 20 mm transcatheter heart valve (THV) implantation. The purpose of this study was to investigate the short term outcomes of Sapien 3 20 mm THV implantation in Japanese people with a small body size. Methods: We retrospectively collected the hospital records of consecutive patients who underwent TAVI using the Sapien 3 20 mm THV between October 2016 and March 2017. Clinical and echocardiographic data from before and one week after TAVI were collected. Results: Six Japanese patients (all female, mean age 89 ± 5 years, body surface area [BSA] 1.29 ± 0.16m2) received a Sapien 3 20 mm THV. All the procedures were feasible and successful, and the 30-day mortality rate was 0%. The functional class and the echocardiographic findings significantly improved (aortic valve area, 0.5 ± 0.1 cm2 to 0.8 ± 0.1cm2; mean pressure gradient, 55 ± 15 mmHg to 19 ± 7 mmHg; P = .043, respectively). However, the values of the indexed effective orifice area in all patients after Sapien 3 20 mm THV implantation were less than 0.85 cm2/m2, suggesting prosthesis-patient mismatch (PPM). Conclusions: The implantation of a Sapien 3 20 mm THV was safe and effective in high surgical risk elderly Japanese patients with a small body size. PPM after Sapien 3 20mm THV may be prevalent among Asians with small body sizes. Careful clinical follow-up will be necessary after Sapien 3 20 mm THV implantation.

scholarly journals First-in-Human Use of the Next-generation ProtEmbo Cerebral Embolic Protection System During Transcatheter Aortic Valve-in-valve Implantation

2021 ◽  
Vol 16 (Supplement 1) ◽  
pp. 1-4
Author(s):  
Dariusz Jagielak ◽  
Radoslaw Targonski ◽  
Dariusz Ciecwierz
Keyword(s):  
Aortic Valve ◽  
Aortic Arch ◽  
Aortic Regurgitation ◽  
Heart Valve ◽  
Transcatheter Aortic Valve ◽  
Transcatheter Heart Valve ◽  
Valve In Valve ◽  
Human Use ◽  
Valve Implantation

Cerebral embolic protection (CEP) devices aim to reduce the risk of periprocedural cerebrovascular events during transcatheter aortic valve implantation (TAVI). Here, the authors describe the first-in-human experience with the ProtEmbo Cerebral Protection System (Protembis), a next-generation CEP device, during TAVI. This case is part of a larger European trial evaluating the safety and performance of this device. After deployment of the ProtEmbo in the aortic arch, a first transcatheter heart valve was implanted. Despite postdilatation, moderate to severe aortic regurgitation persisted. The operating team decided to perform a valve-in-valve procedure using a second transcatheter heart valve. The ProtEmbo demonstrated good coverage of all three head vessels and no interaction with TAVI catheters in the aortic arch throughout the entire procedure. No adverse events were observed during hospitalisation or follow-up, and there was a significant reduction in aortic regurgitation at follow-up echocardiography. Despite a challenging overall procedure with presumably high embolic burden, diffusion-weighted MRI at follow-up showed a low number (n=3) and volume (156 mm3) of new hyperintense lesions. The first-in-human use of the ProtEmbo was safe and feasible, despite a challenging TAVI valve-in-valve procedure.

Sign in / Sign up

Export Citation Format

Share Document